The Quantify Research team – Kirk Geale, Alexander Rieem Dun, and Gustaf Ortsäter – collaborated with our esteemed colleagues Jacob Pontoppidan Thyssen, Dan Henrohn MD, PhD, MSc Pharm, RPh, Maureen P. Neary, PhD, MS, Ingrid Schager, Anna De Geer, Petra Neregård, Amy C., Joe Cappelleri, William Romero, MD., and Laura von Kobyletzki on this groundbreaking, Pfizer-sponsored study.
? Scope: The study delved into comorbid conditions within the Swedish adult atopic dermatitis (AD) population, encompassing over 200,000 individuals (both AD patients and non-AD reference individuals), with more than 1.2 million person-years of follow-up.
? Key Findings: With almost 100 individual conditions grouped into 14 comorbidity-categories, the results underscore the substantial clinical burden of AD. Adult patients face an increased risk of developing numerous comorbid conditions that extend well beyond atopic disorders.
? We’re proud of the impactful research our team has contributed to advancing our understanding AD. Read the full article to explore the comprehensive insights gained from this extensive study!
? You can find the full open-access study here:
? This study complements our recent publication on comorbidity burden in pediatric dermatitis, found here:
Get in touch to find out more about how the Nordic data landscape can enable large-scale, high-impact research.
